LSV Asset Management Has $20.69 Million Stock Position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

LSV Asset Management lessened its stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 0.8% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,230,700 shares of the biopharmaceutical company’s stock after selling 10,069 shares during the quarter. LSV Asset Management owned approximately 1.05% of Catalyst Pharmaceuticals worth $20,688,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in CPRX. SG Americas Securities LLC bought a new stake in Catalyst Pharmaceuticals in the 3rd quarter valued at $502,000. Zurcher Kantonalbank Zurich Cantonalbank grew its stake in Catalyst Pharmaceuticals by 25.7% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 24,692 shares of the biopharmaceutical company’s stock valued at $289,000 after buying an additional 5,044 shares during the last quarter. Assetmark Inc. raised its holdings in Catalyst Pharmaceuticals by 11.1% in the 3rd quarter. Assetmark Inc. now owns 62,173 shares of the biopharmaceutical company’s stock valued at $727,000 after acquiring an additional 6,218 shares during the period. Teacher Retirement System of Texas lifted its position in Catalyst Pharmaceuticals by 5.3% during the third quarter. Teacher Retirement System of Texas now owns 28,682 shares of the biopharmaceutical company’s stock worth $335,000 after acquiring an additional 1,456 shares during the last quarter. Finally, Jackson Creek Investment Advisors LLC bought a new stake in shares of Catalyst Pharmaceuticals during the third quarter worth approximately $797,000. 79.22% of the stock is owned by institutional investors.

Catalyst Pharmaceuticals Trading Up 1.8 %

Shares of Catalyst Pharmaceuticals stock opened at $14.99 on Tuesday. The company has a market cap of $1.77 billion, a PE ratio of 24.57, a price-to-earnings-growth ratio of 0.81 and a beta of 0.89. The company has a 50 day moving average of $15.67 and a 200-day moving average of $14.73. Catalyst Pharmaceuticals, Inc. has a 1-year low of $11.09 and a 1-year high of $17.76.

Catalyst Pharmaceuticals (NASDAQ:CPRX) last released its earnings results on Wednesday, February 28th. The biopharmaceutical company reported $0.49 earnings per share for the quarter, topping the consensus estimate of $0.45 by $0.04. The firm had revenue of $110.57 million during the quarter, compared to analysts’ expectations of $105.78 million. Catalyst Pharmaceuticals had a return on equity of 26.56% and a net margin of 17.93%. Research analysts forecast that Catalyst Pharmaceuticals, Inc. will post 1.81 earnings per share for the current year.

Insider Buying and Selling

In related news, Director David S. Tierney sold 25,000 shares of Catalyst Pharmaceuticals stock in a transaction that occurred on Monday, April 8th. The shares were sold at an average price of $15.68, for a total transaction of $392,000.00. Following the sale, the director now directly owns 348,874 shares of the company’s stock, valued at approximately $5,470,344.32. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 11.00% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

A number of brokerages have commented on CPRX. Oppenheimer reaffirmed an “outperform” rating and issued a $29.00 price objective on shares of Catalyst Pharmaceuticals in a report on Wednesday, March 27th. TheStreet upgraded shares of Catalyst Pharmaceuticals from a “c+” rating to a “b” rating in a research note on Tuesday, March 12th. Bank of America began coverage on shares of Catalyst Pharmaceuticals in a research report on Thursday, March 7th. They set a “buy” rating and a $23.00 target price on the stock. HC Wainwright reiterated a “buy” rating and issued a $24.00 price target on shares of Catalyst Pharmaceuticals in a research report on Friday, March 1st. Finally, Citigroup assumed coverage on Catalyst Pharmaceuticals in a research report on Thursday, March 14th. They set a “buy” rating and a $27.00 price target on the stock. Six analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average price target of $26.43.

Catalyst Pharmaceuticals Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.